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Abstract
Background: Glioblastoma is a highly lethal neoplasm that frequently recurs locally after radiotherapy, and most of
these recurrences originate from near the irradiated target field. In the present study, we identified the effects of
radiation on glioma invasion and p53, TIMP-2, and MMP-2 expression through in vitro and in vivo experiments.
Methods: The U87MG (wt p53) and U251 (mt p53) human malignant glioma cell lines were prepared, and the
U2OS (wt 53) and Saos2 (del p53) osteosarcoma cell lines were used as p53 positive and negative controls. The four
cell lines and p53 knock-downed U87MG cells received radiation (2–6 Gy) and were analyzed for expression of p53
and TIMP-2 by Western blot, and MMP-2 activity was detected by zymography. In addition, the effects of irradiation
on directional invasion of malignant glioma were evaluated by implanting nude mice with bioluminescent u87-Fluc
in vivo followed by MMP-2, p53, and TIMP-2 immunohisto-chemistry and in situ zymography.
Results: MMP-2 activity and p53 expression increased in proportional to the radiation dose in cell lines with wt
p53, but not in the cell lines with del or mt p53. TIMP-2 expression did not increase in U87MG cells. MMP-2 activity
decreased in p53 knock-downed U87MG cells but increased in the control group. Furthermore, radiation enhanced
MMP-2 activity and increased tumor margin invasiveness in vivo. Tumor cells invaded by radiation overexpressed
MMP-2 and p53 and revealed high gelatinolytic activity compared with those of non-radiated tumor cells.
Conclusion: Radiation-induced upregulation of p53 modulated MMP-2 activity, and the imbalance between
MMP-2 and TIMP-2 may have an important role in glioblastoma invasion by degrading the extracellular matrix.
Bioluminescent “U87-Fluc”was useful for observing tumor formation without sacrifice after implanting tumor
cells in the mouse brain. These findings suggest that the radiotherapy involved field for malignant glioma needs
to be reconsidered, and that future trials should investigate concurrent pharmacologic therapies that inhibit
invasion associated with radiotherapy.
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Background
Glioblastoma (GBM) is the most malignant of primary
adult brain tumors and is characterized by a highly local-
ized invasive cell population, abundantly proliferative cells,
neoangiogenesis, and necrosis. The current treatment
standard involves a multimodal approach of neurosurgery,
fractionated radiotherapy (RT), and chemotherapy [1].
However, despite continuous improvements in GBM
treatment, median survival time does not exceed
15 months [2].
RT is the main treatment for brain tumors. The RT tar-
get volume consists of the tumor volume with a 2–3 cm
margin of surrounding tissue, which is considered to be at
risk for microscopic tumor invasion. Traditional target-
volume RT has raised a question of whether RT could
be helpful for killing tumor cells that have infiltrated the
surrounding normal brain. In fact, whole brain RT has
not decreased the risk of recurrence and has seriously
increased the risk of neuropsychological deficits, e.g.,
dementia [3]. Furthermore up to 90 % of all gliomas re-
lapse in close proximity to the resection cavity or the post-
operative RT target volume [4, 5]. In other words, it may
be important to understand the biological characteristics
of invading cells into the surrounding brain tissue. Inva-
sive tumor cells have a G0 phase, are resistant to RT and
chemotherapy, and eventually regrow. G0/G1 phase cells
migrate more rapidly and further than cancer cells in the
S/G2/M phases. Cancer cells cease migrating when they
enter the S/G2/M phases and restart migration after cell
division when they re-enter the G0/G1 phase [6]. Radi-
ation to surrounding brain tissue augments secretion of
several mediators, including stromal cell-derived factor-
1α, vascular endothelial growth factor (VEGF) and matrix
metalloproteinases (MMPs), which play a vital role in
tumor invasion and metastasis [7].
MMPs are a family of zinc-dependent proteolytic en-
dopeptidases that break down the structural barriers to
migration and invasion by dissolving and destroying the
matrix proteins of surrounding normal brain tissue [8, 9].
In 2001, Wild-Bode et al. reported that sublethal doses of
radiation promote glioma invasion [10]. Another study
suggested that this may be mediated by MMPs, such as
MMP-2, as irradiation increases MMP-2 levels [11]. In
particular, MMP-2 and 9 are highly expressed in GBM
compared with that in normal brain tissue [1]. Ionizing ra-
diation enhances MMP-2 production in a variety of hu-
man cancers, and activation of wild-type p53 by radiation
and the resulting increase in MMP-2 expression suggest
that radiation may promote invasion-related gene expres-
sion [12–15].
p53, a 53-kDa nuclear protein, is one of the most
extensively studied molecules in cancer research and
molecular biology. p53 has many anticancer functions
and plays critical roles in DNA repair, apoptosis, and
inhibiting angiogenesis [16]. Wild-type p53 is required
to activate apoptosis in response to DNA damage [17]
and, thus, may be a critical determinant of the effective-
ness of ionizing radiation and chemotherapeutic agents.
According to a 1995 report, patients with cancer harbor-
ing a p53 mutation often have poorer prognoses than
those with tumors that harbor wild-type p53 [18]. Thus,
the genetic and functional status of the p53 gene is an
important factor guiding therapeutic strategies in pa-
tients with cancer [19]. In 1997, after a computer search
for other potential p53 target genes, Bian et al. deter-
mined that wild-type p53 binds the promoter of the gene
encoding human type IV collagenase (also called gelati-
nase A or MMP-2), a naturally occurring enzyme subject
to inhibition by TIMP-2, among other known p53 target
genes [14, 20].
In this study, we investigated the effects of radiation
on malignant glioma invasion and p53, TIMP-2, and
MMP-2 expression through in vitro and in vivo experi-
ments. As focal brain irradiation remains the standard of
care for managing malignant glioma, understanding the
effects of RT on invasion of malignant glioma may im-
pact RT strategy. We hope that our findings will help
understanding the changes occurring in surrounding
normal brain tissues within the postoperative RT field
and provide a basis for explaining local relapse during or
a few months after RT.
Materials and methods
Cell culture conditions
The human malignant glioma cell lines U87MG (wt p53)
and U251 (mt p53) and the human osteosarcoma cell lines
U2OS (wt p53) and SAOS (del p53) were acquired from
the American Type Culture Collection (Manassas, VA,
USA). The U87-Fluc cell line, which is transfected with a
lentiviral vector containing the firefly luciferase (Fluc)
gene, was a gift from Professor Min (Hwasun Chonnam
National University Hospital, Korea). The cell lines were
routinely maintained in high-glucose DMEM (Gibco BRL,
Gaithersburg, MD, USA) supplemented with 10 % fetal
bovine serum (Gibco) and maintained at 37 °C containing
5 % CO2/95 % air.
siRNA oligonucleotide transfection
A siRNA oligonucleotide was used for p53 knockdown.
The synthesized p53 siRNA (5′-CACUACAACUACAU
GUGUA-3’) and scrambled RNA (negative control) were
purchased from Bioneer (Daejeon Korea). Approximately
2 × 105 u87MG cells were seeded on a plate and trans-
fected with the siRNA oligonucleotide using Lipofecta-
mine™ RNAiMAX (Invitrogen, Carlsbad, CA, USA),
according to the manufacturer’s instructions. p53 knock-
down was confirmed by Western blotting.
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Radiation
The cell lines were grown in 60 mm culture dishes until
80–90 % confluent and then the media were replaced
with serum free media to synchronize the cell cycle. The
cells were exposed to radiation from a Gammacell 1000
unit (137Cs; Nordion, Kanata, ONT, Canada) at 2, 4, and
6 Gy. The irradiated cells were further cultured for 24 h
and harvested.
Preparation of total protein and conditioned medium
The cells were lysed with a protein extraction buffer
[50 mM Tris (pH 8.0), 5 mM EDTA, 150 mM sodium
chloride, 0.5 % deoxycholic acid, 0.1 % sodium dodecyl
sulfate (SDS), 1 % NP-40, 1 mM phenylmethylsulfonyl
fluoride, and 1 mg/ml protease inhibitor cocktail] to pre-
pare total protein. The cells were grown in 60 mm cul-
ture dishes until subconfluent, and the media were
replaced with serum-free medium to prepare the condi-
tioned medium. After radiation exposure, the cells were
incubated at 37 °C for 24 h. The conditioned media were
clarified by centrifugation, and protein concentrations
were determined using a protein assay kit (Bio-Rad,
Hercules, CA, USA).
Western blot
Whole cell lysates (20 μg) were separated by 8–10 %
SDS-polyacrylamide gel electrophoresis and transferred
to PVDF membranes (Pall Corp., Port Washington, NY,
USA). The membranes were incubated for 2 h at room
temperature with 5 % non-fat dry milk, probed over-
night at 4 °C with actin, p53, TIMP-2, and MMP-2 anti-
bodies (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and incubated with a horseradish peroxidase-
labeled goat anti-rabbit IgG (Jackson Immunoresearch
Laboratory, West Grove, PA, USA). Bound secondary
antibody was detected by enhanced chemiluminescence
(Amersham Biosciences, Bucks, UK), and protein levels
were determined by autoradiography using a LAS-4000
instrument (Fuji, Tokyo, Japan).
Gelatin zymography
Twenty μg of proteins in conditioned media were mixed
with sample buffer (50 mM Tris–HCl, 2 % SDS, 0.1 %
bromophenol blue, and 10 % glycerol) before electrophor-
esis. Aliquots were electrophoresed on 8 % SDS-
polyacrylamide gels containing 1 mg/ml type A gelatin
(Sigma-Aldrich, St. Louis, MO, USA). Each gel was
washed three times for 30 min in 2.5 % Triton X-100 and
then incubated for 20 h at 37 °C in incubation buffer
[50 mM Tris–HCl (pH 7.5), 10 mM CaCl2, and 200 mM
NaCl]. The gels were stained with Coomassie Brilliant
Blue R-250 (0.2 % Coomassie Brilliant Blue R-250, 20 %
methanol, 10 % acetic acid in water) and then destained in
20 % methanol and 10 % acetic acid in water.
In vivo studies
Five- to six-week old male BALB/c athymic nu−/nu −
mice (body weight, 20–30 g) were purchased from the
Orient Co. (Seongnam, Korea). They were housed in
groups of three or four under standard conditions at a
temperature of 22 °C and a 12-h light/12-h dark cycle.
The mice had free access to standard food pellets and
tap water. The mice were anesthetized with isoflurane
(2 %), and a mixture of ketamine (200 mg/kg) and xyla-
zine (10 mg/kg) for irradiation. Radiation treatment
was carried out 14–21 days after tumor implantation.
Tumor growth was monitored twice weekly by optical
bioluminescence imaging, and signals were observed
in all animals 7 days after tumor implantation. All
animal care, experiments, and euthanasia were per-
formed in accordance with protocols approved by the
Chonnam National University Animal Research Committee
(Gwangju, Korea).
Bioluminescence imaging
Anesthetized mice were placed in the light-tight cham-
ber of the IVIS 100 imaging system (Caliper, Newton,
MA, USA), equipped with a cooled charge-coupled
device camera to obtain the tumor bioluminescence
images. Photons emitted from the luciferase-expressing
tumor were collected and integrated over 1-min pe-
riods. Pseudocolor images indicating photon counts
were overlaid on photographs of the mice using Living
Image software v. 2.25 (Caliper). A region of interest
was selected manually based on signal intensity. The
area of the region of interest was kept constant, and in-
tensity was recorded as maximum radiance within each
region of interest.
Radiotherapy
RT was commenced 2 weeks after tumor implantation.
A 6-MV X-ray was used via a linear accelerator
(CLINAC 21EX; Varian, Palo Alto, CA, USA). The
source to skin distance was 97.5 cm with a field size of
5 × 5 cm2 and a dose rate of 3 Gy/min. Water equivalent
boluses of 1 cm thickness were placed under and above
the tumor-bearing mouse brain to establish dose homo-
geneity. Additional file 1: Figure S1 illustrates the
process to assess the radiation effect on brain tumors in
vivo. After implanting the U87-Fluc cells in the brain,
tumor bioluminescence of mouse brain cells bearing
U87-Fluc was observed continuously from day 10 to 28
using the IVIS 100 imaging system. Radiation exposure
was either a single 6 Gy dose or 2 Gy fractions five times
for 7 days on day 14 after U87-Fluc implantation. The
mice brain tissue was stained with hematoxylin and
eosin (H&E) or immunohistochemical staining after kill-
ing the mice on day 30.
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Histopathology
All mice were anesthetized and perfused transcardially
with 4 % ZBF-containing 36.7 mM ZnCl2, 27.3 mM
ZnAc2 · 2H2O, and 0.63 mM CaAc2 in 0.1 M Tris,
pH 7.4. The brain tumor was removed, fixed in the same
solution for 36–38 h at room temperature and then
dehydrated for paraffin embedding. The tumors were
blocked in cross-section and processed for paraffin
embedding.
Four μm-thick consecutive sections were cut from the
recipient blocks and placed on poly-L-lysine-coated slides
for immunohistochemistry. Representative sections were
stained with H&E. Heat-induced epitope retrieval was
carried out for 10 min at 120 °C in a pressure cooker in
10 mM citrate buffer, pH 6.0 (Tris–EDTA buffer, pH 9.0
was used to detect MMP-2). Endogenous peroxidase ac-
tivity was blocked by incubating the samples in PBS con-
taining 3 % H2O2, and the non-specific binding sites were
blocked with 3 % bovine albumin (Sigma-Aldrich) in PBS
for 20 min at room temperature. The following primary
monoclonal antibodies were added: MMP-2 (1:8000;
Lab Vision Corp. Fremont, CA, USA), glial fibrillary
acidic protein (GFAP) (1:4000, Lab Vision Corp), and
p53 (1:8000; Santa Cruz Biotechnology). Then, a
biotin-labeled secondary antibody (Dako, Carpinteria, CA,
USA) was added, and the samples were incubated at room
temperature for 1 h. A streptavidin-horseradish peroxid-
ase (Dako) detection system was applied to the capillary
channels, followed by a 20 min incubation at room
temperature. The tissue sections were ready for the
chromogen reaction with diaminobenzidine. Counter-
staining was performed with Harris hematoxylin. Con-
trol experiments were performed in all specimens at
the time of immunostaining using the secondary anti-
body alone.
In situ zymography
In situ zymography was performed to localize gelatinoly-
tic activity, essentially as described by Sbai et al. [21] and
Miller et al. [22]. Eight-mm-thick sections were cut from
the same tissue used for immunohistochemistry. The
fixed, paraffin-embedded tissue sections were heated to
59 °C overnight, deparaffinized in xylene, and rehydrated
in a graded alcohol series. The substrate was prepared
by dissolving 1 mg DQ gelatin in 1 ml Milli-Q water,
followed by a 1:50 dilution in a reaction buffer contain-
ing 50 mM Tris–HCl, 150 mM NaCl, 5 mM CaCl2, and
0.2 mM sodium azide (pH 7.6). Of this mixture, 250 μl
was placed on top of the tissue sections, covered with
Parafilm, and incubated in a dark humidity chamber at
37 °C. The Parafilm was removed gently after 2 h, and
the sections were rinsed with Milli-Q water and fixed in
4 % neutral-buffered formalin for 10 min in the dark.
Sample autofluorescence was quenched in a 100 mg/ml
NaBH4 solution for 30 min. The sections were rinsed in
a PBS bath (2 × 5 min) and mounted with glycerol con-
taining DAPI to counterstain the nuclei. Control slides
were pre-incubated with 20 mM EDTA for 1 h to verify
the contribution of MMPs. A 20 mM EDTA solution
was also added to the substrate. Tissue autofluorescence
level was evaluated by incubating control sections at
220 °C for 2 h immediately after the substrate had been
added. Fluorescence was evaluated using an Olympus
confocal laser microscope with Olympus Application
Suite Advanced Fluorescence software (Tokyo, Japan).
Statistical analyses
Each experiment was repeated at least three times to con-
firm reproducibility. Comparisons were made using one-
way analysis of variance. Differences between means were
evaluated using the Kruskal–Wallis test, and p-values < 0.05
were considered significant.
Results
Effect of radiation on MMP-2 activity according to p53
status
The human malignant glioma cell lines U87MG (wt
p53) and U251 (mt p53) and the human osteosarcoma
cell lines U2OS (wt p53) and SAOS (del p53) were se-
lected to measure the effect of radiation on p53 expres-
sion and MMP-2 activity. As shown Fig. 1, MMP-2
activity and p53 expression increased in U87MG and
U2OS cells wt p53 in proportion to the radiation dose,
but these were unchanged in U251 and SAO2 cells.
TIMP-2 is an endogenous MMP-2 inhibitor, and the bal-
ance between TIMP-2 and MMP-2 is a critical deter-
minant of malignant glioma invasion. We performed a
Western blot for TIMP-2 in the four cell lines exposed
to radiation. TIMP-2 expression did not change after ra-
diation exposure in three of the cell lines, except U2OS.
The sublethal radiation dose increased p53 expression
and MMP-2 activity in U87MG cells without a corre-
sponding increase in TIMP-2 (p < 0.05, Fig. 1a, b, c). In
contrast, TIMP-2 expression and MMP-2 activity in
U2OS cells with wt p53 increased simultaneously follow-
ing radiation. These results suggest that TIMP-2 expres-
sion was likely to be different depending on the cell
type, and that the imbalance between TIMP-2 and
MMP-2 expression may enhanced tumor invasion. In
addition, MMP-2 activity caused by radiation may be as-
sociated with p53 status.
Radiation-induced p53 upregulation is responsible for
promoting MMP2 activity
MMP-2 activity and p53 expression simultaneously in-
creased after radiation exposure, and the MMP-2 gene
promoter region has a putative p53 binding site. Thus,
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we identified whether p53 actually enhanced radiation-
induced MMP-2 activity. U87MG was transfected p53
siRNA oligonucleotide and was performed Western
blot for p53 and TIMP-2 (Fig. 2a), and Zymography for
determining of MMP-2 activity (Fig. 2b). p53 expres-
sion and MMP-2 activity increased in proportion to the
radiation dose in control transfected scramble RNA to
U87MG cells, but remained unchanged in p53 knock-
down U87MG cells (Fig. 2a, b). TIMP-2 expression was
not changed by radiation, and no difference in TIMP-2
expression was detected between the control and p53
knockdown U87MG cells.
Establishment of a bioluminescent tumor cell line
We established the bioluminescent tumor cell line
“U87-Fluc” for in vivo experiments, in which u87MG
was transfected with firefly luciferase (Fluc). This is a
useful tool to observe tumor formation without sacri-
fice after implanting tumor cells in the mouse brain.
The U87-Fluc cell line emitted photons when D-
luciferin was added (Fig. 3a), and U87-Fluc cells
increased p53 expression and MMP-2 activity in pro-
portion to the radiation dose but did not affect TIMP-
2 expression (Fig. 3b, c). MMP-2 activity increased
depending on the incubation time after radiation ex-
posure and showed a great difference between control
and radiated cells after 24 hr (p < 0.05, Fig. 3d).
Tumor growth rate analyses using optical
bioluminescence imaging
U87-Fluc-bearing nude mice brains were observed con-
tinuously by tumor bioluminescence using the IVIS 100
imaging system to determine the effects of radiation on
tumor growth. Additional file 1: Figure S1 illustrates the
p53
TIMP-2
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Fig. 1 Radiation effect on p53, TIMP2 expression and MMP-2 activity in 2 cell lines with wt p53 and 2 cell lines without p53. Each cell lines were
exposed 0, 2, 4, 6 Gy, respectively. MMP-2 activity was detected using zymography (one lane) and expression of TIMP-2 and p53 was detected
using western blot (2–4 lane) a Glioblastoma cell lines; b MMP-2 activity of U87MG and U251; c p53 density of U87MG and U251; d Osteosarcoma
cell lines
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process used to assess the radiation effects on brain tu-
mors in vivo. The mouse brains were exposed to radi-
ation after tumor formation had been observed by
tumor bioluminescence. As shown in Fig. 4, notable re-
tardation of tumor growth was observed in the single
6 Gy exposed group, compared with that in the control
groups. However, the brain tumors continued to grow,
and the final growth rate was similar to that of the con-
trol group from about day 20. No difference was found
in the radiation-fractionated group, compared to the
control group, indicating that the single dose (6 Gy)
treatment or low dose fractionated irradiation was insuf-
ficient for complete control of tumor growth.
Irradiation promotes glioma cell dissemination in vivo
The observed invasive effect of sublethal irradiation in
U87-Fluc cells in vivo may have clinical relevance. As
shown in Fig. 5 tumors in the non-radiated group had
clear borders, whereas in the radiated group showed
more irregular margin, the diffuse infiltration of tumor













Fig. 3 Radiation effect on p53, MMP-2 and TIMP-2 in U87 MG-Fluc cells. Establishment bioluminescent tumor cells “U87-Fluc” which is transfected
with firefly luciferase (fluc) in u87MG. a Photons emitted from U87-Fluc cell line when D-luciferin was added; b Western blot; c Zymography for
detection MMP-2 activity in dependent on time; d Density of MMP-2 activity. It had been showed statistical significance between control and
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Fig. 2 Radiation effect on p53, TIMP2 expression and MMP-2 activity in p53 knockdown U87MG. ‘Control’ Scramble RNA transfected U87MG,
‘siRNA for p53’ is p53 knock-downed U87MG using siRNA technology. a Western blot; b Zymography for MMP-2 activity
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The in vitro results showed an association between
p53 and MMP-2. We wanted to confirm whether tumor
cells invading after radiation exposure was related with
p53 expression and MMP-2 activity. Thus, we verified
that the invasive cells surrounding normal brain were
malignant glioma cells using GFAP staining as a glial cell
marker, and performed immunohistochemistry for p53
and MMP-2. p53 was highly expressed in irradiated tu-
mors and was particularly distributed in invasive tumor
cells around the margin area (Fig. 6), even though no
difference was observed between the single and the frac-
tionated dose groups. GFAP and p53-positive cells were
distributed similarly.
In situ zymography was performed in radiation-
exposed and unexposed nude mouse brains. This is a
unique technique that enables localization of gelatinoly-
tic activities in histological sections. Notably, autofluo-
rescence during in situ zymography was minimized by
NaBH4. Green fluorescence as a signal for gelatinolytic
activity was found around the tumor margin area in the
radiated group but not in non-radiated group (Fig. 7c, d).
However, MMP-2 expression showed no difference be-
tween the two groups (Fig. 7b).
Discussion
Primary GBM represents about 90 % of GBMs, and the
wild-type p53 gene is present in about 70 % of primary
GBMs. However, p53 occurs less frequently in secondary
GBMs (35 %) [23]. p53 mutations frequently occur in
low grade gliomas (WHO grade II astrocytoma) [24]
and, thus, are a frequent event in the pathological pro-
gression of secondary GBM (WHO Grade IV) [25]. Sec-
ondary GBM arises from a preexisting grade II or III
astrocytoma, whereas a primary GBM forms de novo.
p53 mutations were detected in only 40 % of the sam-
ples, predominantly in anaplastic astrocytomas, indicat-
ing that >50 % of patients have wild type p53 [21].
In this study, we identified RT effect on migration
and invasion of malignant glioma and studied the asso-
ciation between p53 and MMP-2 through in vitro and
in vivo study. p53 is well known as a radio-sensitizer





Fig. 4 Tumor growth rate analyses using Optical Bioluminescence Imaging. U87-Fluc bearing nude mice brain were continuously observed
through tumor bioluminescence by the IVIS 100 imaging system. For pilot study we designated control group (non-radiated group) and two
groups (radiated group). Among radiated group, one group was exposed to fractionated dose radiation (2Gy x 5) and another group was
exposed to single dose radiation (6 Gy)
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hypothesized that RT may promote tumor metastasis in
a subset of human cancers harboring the wild-type p53
gene [3]. Increased p53 expression affects the meta-
static potential of certain types of cancers [15, 22].
Radiation-induced p53 upregulation is responsible for
promoting the VEGF-MMP2 pathway involved in en-
hancing the invasiveness of both irradiated and by-
stander hepatoma cells [26].
MMPs are a family of extracellular matrix (ECM)-de-
grading enzymes associated with numerous physiological
and pathological events, such as malignant tumor cell in-
vasion processes [8, 9]. And MMP activity is regulated at
multiple levels, such as at the level of gene transcription
and the synthesis of pro-MMPs. Ionizing radiation is
known as a representative of DNA-damaging agents. The
DNA cleavage by irradiation leads to the accumulation of
p53 and its translocation into the nucleus [27, 28].
Then, the activated p53 binds to DNA in a sequence-
specific manner and modulates a set of genes [29]. Other
study has demonstrated that the promoter region of the
MMP-2 gene has a putative p53 binding site and that
wild-type p53 transcriptionally upregulates the expres-
sion of MMP-2 mRNA [14, 22]. Considering the above
references, we examined the radiation effect on MMP-2
activity and association between p53 status and MMP-2
activity. In our study, MMP-2 activity was actually in-
creased depending on the radiation dose in cell lines
with wt p53 gene; however, no change of MMP-2 activity
was shown in cell lines with mt p53 gene. So we ex-
pected that p53 increased by radiation could upregulate
MMP-2 activities, then confirmed their association using
p53 knock-downed u87MG cells by siRNA technology.
MMP-2 activity was decreased regardless of the radi-
ation dose in p53 knockdown, while increased depend-
ing on the radiation dose in the control. Even though
further studies are required to identify direct association
between p53 and MMP-2 activity, p53, at least, can
modulate the change of MMP-2 activity by radiation on
the basis of the present study.
Many studies have reported the effects of radiation on
tumor cell migration, invasion, and surrounding healthy
tissue. Radiation enhances cell invasion and induces
MMP-2 and −9 activities in various tumors and in lung
epithelial cells [30–32]. Surrounding the brain tissue ex-
posed to radiation secretes several mediators, such as
VEGF, MMPs, cyclooxygenase-2, and transforming growth
factor-beta, all of which play vital roles in tumor invasion
and metastasis [26, 33, 34]. An imbalance between MMP-
2 and TIMP-2 has an important role in glioma invasion by
degradation of the ECM [34, 35]. TIMP-2 is an endogen-
ous MMP-2 inhibitor and critical for maintenance of tissue
homeostasis by suppressing proliferation of quiescent cells
in response to angiogenic factors, and by inhibiting prote-
ase activities in tissues undergoing ECM remodeling. Our
results showed that the expression of TIMP-2 was not











Fig. 5 Hematoxyin and Eosin staining of brain tissues. Exposure to radiation was more invasive and exhibited multiple tumor cell satellites, while
non-radiated tumor showed less invasiveness and clear margin. a Non-radiated group, b Radiated group (Single dose), c Radiated
group (fractionation)
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the radiation dose in malignant glioma cell lines. We also
obtained the same results through in vivo experiments.
The radiation-exposed U87-Fluc-bearing mouse brain was
significantly more invasive, while MMP-2 and p53 expres-
sion, as well as gelatinolytic activity, increased, particularly
in margin areas. However, TIMP-2 expression increased
along with MMP-2 activity in U2OS cells. Those results
suggest that TIMP-2 expression was likely to be different
depending on the organ specific cell type, and that the im-
balance between TIMP-2 and MMP-2 in malignant glioma
with wt p53 may be important to understanding radiation-
enhanced glioma invasion. Finally, we confirmed that radi-
ation could induce glioma invasion through in vivo brain
tumor model using U87-Fluc cell with bioluminescent.
The U87-Fluc-bearing mouse brain was observed continu-
ously using tumor bioluminescence with the IVIS 100 im-
aging system. This is a useful tool to observe tumor
formation without sacrificing animals after implanting
tumor cells. As shown through the results, radiation sig-
nificantly enhanced tumor cell invasion in the U87-Fluc-
bearing mouse brain tumor model. We suggest that inva-
sive brain tumor model caused by RT could be applied to
in vivo studies for verification of the effect of anti-invasive
therapeutic target genes or drugs.
The clinical implications of this study are as follows:
a) Alterations of radiotherapy for human malignant
glioma might be considered to determine whether
the patient is harboring wild-type p53 or mutant
type.
b) We propose using an MMP inhibitor adjunctively to
suppress the radiation-induced increase in MMP-2
expression and to prevent unexpected or unwanted
tumor invasion due to RT.
Conclusions
Radiation enhanced glioma invasion in the mouse brain
tumor model. Wild type p53 induced by raidation modu-
lated MMP-2 activity, and the imbalance between MMP-2
and TIMP-2 may have an important role in glioma inva-
sion by degradation of the ECM. For the study using
mouse brain tumor model, bioluminescent U87-Fluc was
useful to observe tumor formation without sacrificing ani-
mals after implanting tumor cells. Taken together, these








Fig. 6 Immunohistochemistry for p53 and GFAP in brain tissues. GFAP (d,e,f) as a glial cell marker was stained to confirm whether p53 (a,b,c)
positive cells were glioma cell or not
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findings suggest that involved-field RT for malignant gli-
omas may need to be reconsidered. Future trials should
consider pharmacological therapies that inhibit invasion
concurrently with RT.
Additional file
Additional file 1: Figure S1. The illustration of the experimental
process to assess radiation effect on brain tumor in vivo. After
implantation U87-Fluc cells into brain, tumor bioluminescence of mouse
brain bearing U87-Fluc was continuously observed from day 10 to 28
using the IVIS 100 imaging system. Radiation was exposed to either
Single dose 6Gy or 2Gy fractions 5 times for 7 days on 14 day after
U87-Fluc implantation. Mice brain were performed with Hematoxylin
and eosin or immunohistochemical staining after execution on 30 day.
(PPTX 381 kb)
Abbreviation
GBM: Glioblastoma; RT: RadioTherapy; wt: Wild type; mt: Mutant type;
del: deletion; MMP: Matrix metalloproteinase; TIMP: Tissue inhibitor of Matrix
metalloproteinase; EDTA: Ethylenediaminetetraacetic acid.
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